• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5071156)   Today's Articles (74)
For: Kesselheim AS, Tan YT, Avorn J. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff (Millwood) 2016;34:286-93. [PMID: 25646109 DOI: 10.1377/hlthaff.2014.1038] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Number Cited by Other Article(s)
1
Gentilini A, Neez E, Wong-Rieger D. Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2025;28:680-685. [PMID: 39880194 DOI: 10.1016/j.jval.2024.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 12/10/2024] [Accepted: 12/19/2024] [Indexed: 01/31/2025]
2
Nijim S, Korsunska A, Zinski J, Bolden SE, Zuccato M, Repasky M, Fajgenbaum DC. Rare Disease Drug Repurposing. JAMA Netw Open 2025;8:e258330. [PMID: 40323602 PMCID: PMC12053540 DOI: 10.1001/jamanetworkopen.2025.8330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Accepted: 03/01/2025] [Indexed: 05/08/2025]  Open
3
Nishimura S, Ma C, Sidransky E, Ryan E. Obstacles to Early Diagnosis of Gaucher Disease. Ther Clin Risk Manag 2025;21:93-101. [PMID: 39882275 PMCID: PMC11776414 DOI: 10.2147/tcrm.s388266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2024] [Accepted: 01/11/2025] [Indexed: 01/31/2025]  Open
4
Scholte M, Grimm SE, Pauly B, Verbeeck F, Pasmooij AMG, Bouma B, van Duijn-Wiersma J, Guney E, Kesselheim AS, Schmidt HHHW, Joore MA. Revising EU pharmaceutical legislation: will it foster drug repurposing? Drug Discov Today 2025;30:104286. [PMID: 39756647 DOI: 10.1016/j.drudis.2024.104286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Revised: 12/20/2024] [Accepted: 12/31/2024] [Indexed: 01/07/2025]
5
Saha S, Chatterjee P, Nasipuri M, Basu S, Chakraborti T. Computational drug repurposing for viral infectious diseases: a case study on monkeypox. Brief Funct Genomics 2024;23:570-578. [PMID: 38183212 DOI: 10.1093/bfgp/elad058] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2023] [Revised: 12/04/2023] [Accepted: 12/12/2023] [Indexed: 01/07/2024]  Open
6
Shukla M, Malik S, Pandya A. Lab on chip for testing of repurposed drugs. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2024;205:71-90. [PMID: 38789187 DOI: 10.1016/bs.pmbts.2024.03.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2024]
7
Morris R, Ali R, Cheng F. Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database. Curr Drug Targets 2024;25:454-464. [PMID: 38566381 DOI: 10.2174/0113894501290296240327081624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 03/05/2024] [Accepted: 03/15/2024] [Indexed: 04/04/2024]
8
Lexchin J. Therapeutic Benefit From New Drugs From Pharmaceutical Companies. JAMA Intern Med 2024;184:52-53. [PMID: 37983036 DOI: 10.1001/jamainternmed.2023.6256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2023]
9
Alonso Ruiz A, Large K, Moon S, Vieira M. Pharmaceutical policy and innovation for rare diseases: A narrative review. F1000Res 2023;12:211. [PMID: 38778810 PMCID: PMC11109548 DOI: 10.12688/f1000research.130809.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/08/2023] [Indexed: 05/25/2024]  Open
10
Sánchez Fernández I, Gaínza-Lein M, Amengual-Gual M, Barcia Aguilar C, Romeu A, Torres A, Jonas R, Douglass LM. Evolution of antiseizure medication use and cost in the United States of America 2006-2021. Seizure 2023;112:128-138. [PMID: 37832279 DOI: 10.1016/j.seizure.2023.10.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 10/08/2023] [Accepted: 10/09/2023] [Indexed: 10/15/2023]  Open
11
Mandal N, Rath SL. Identification of inhibitors against SARS-CoV-2 variants of concern using virtual screening and metadynamics-based enhanced sampling. Chem Phys 2023;573:111995. [PMID: 37342284 PMCID: PMC10265933 DOI: 10.1016/j.chemphys.2023.111995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 05/12/2023] [Accepted: 06/11/2023] [Indexed: 06/22/2023]
12
Moir J, Aggarwal S, Skondra D. Repurposing medications for treatment of age-related macular degeneration: Insights from novel approaches to data mining. Exp Biol Med (Maywood) 2023;248:798-810. [PMID: 37452694 PMCID: PMC10468640 DOI: 10.1177/15353702231181188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]  Open
13
Ou SL, Luo J, Wei H, Qin XL, Jiang Q. Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers. Front Pharmacol 2023;14:1106961. [PMID: 37153768 PMCID: PMC10160363 DOI: 10.3389/fphar.2023.1106961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 04/10/2023] [Indexed: 05/10/2023]  Open
14
Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res 2022;22:970. [PMID: 35906687 PMCID: PMC9336118 DOI: 10.1186/s12913-022-08272-z] [Citation(s) in RCA: 89] [Impact Index Per Article: 29.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 06/29/2022] [Indexed: 11/10/2022]  Open
15
European patent protection for medical uses of known products and drug repurposing. Nat Biotechnol 2022;40:465-471. [PMID: 35418638 DOI: 10.1038/s41587-022-01269-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
16
Cook-Deegan R, Kesselheim AS, Sarpatwari A. Updating the Bayh-Dole Act: March-in Rights and Transparency. JAMA 2022;327:923-924. [PMID: 35201276 DOI: 10.1001/jama.2022.0895] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
17
Shah S, Dooms MM, Amaral-Garcia S, Igoillo-Esteve M. Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Front Pharmacol 2022;12:768023. [PMID: 34992533 PMCID: PMC8724568 DOI: 10.3389/fphar.2021.768023] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 11/10/2021] [Indexed: 12/12/2022]  Open
18
Simoens S, Huys I. How much do the public sector and the private sector contribute to biopharmaceutical R&D? Drug Discov Today 2021;27:939-945. [PMID: 34863932 DOI: 10.1016/j.drudis.2021.11.027] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 08/11/2021] [Accepted: 11/25/2021] [Indexed: 11/03/2022]
19
α-Lipoic Acid Exerts Its Antiviral Effect against Viral Hemorrhagic Septicemia Virus (VHSV) by Promoting Upregulation of Antiviral Genes and Suppressing VHSV-Induced Oxidative Stress. Virol Sin 2021;36:1520-1531. [PMID: 34510367 PMCID: PMC8435143 DOI: 10.1007/s12250-021-00440-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Accepted: 06/28/2021] [Indexed: 12/03/2022]  Open
20
Hanisch M, Rake B. Repurposing without purpose? Early innovation responses to the COVID‐19 crisis: Evidence from clinical trials. R&D MANAGEMENT 2021;51:393-409. [PMCID: PMC8014695 DOI: 10.1111/radm.12461] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 12/02/2020] [Accepted: 01/26/2021] [Indexed: 05/23/2023]
21
GPCR_LigandClassify.py; a rigorous machine learning classifier for GPCR targeting compounds. Sci Rep 2021;11:9510. [PMID: 33947911 PMCID: PMC8097070 DOI: 10.1038/s41598-021-88939-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Accepted: 04/12/2021] [Indexed: 02/02/2023]  Open
22
Verbaanderd C, Rooman I, Huys I. Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research. Trials 2021;22:322. [PMID: 33947441 PMCID: PMC8093905 DOI: 10.1186/s13063-021-05273-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 04/15/2021] [Indexed: 12/20/2022]  Open
23
Stability of Antimicrobial Drug Molecules in Different Gravitational and Radiation Conditions in View of Applications during Outer Space Missions. Molecules 2021;26:molecules26082221. [PMID: 33921448 PMCID: PMC8069917 DOI: 10.3390/molecules26082221] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 04/07/2021] [Accepted: 04/09/2021] [Indexed: 11/16/2022]  Open
24
Korenstein D, Kaltenboeck A, Mamoor M, Chimonas S. Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students. MEDICAL SCIENCE EDUCATOR 2021;31:489-494. [PMID: 34457906 PMCID: PMC8368429 DOI: 10.1007/s40670-020-01190-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/10/2020] [Indexed: 06/13/2023]
25
Darrow JJ, Light DW. Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding. Health Aff (Millwood) 2021;40:281-288. [PMID: 33523733 DOI: 10.1377/hlthaff.2020.00328] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
26
Barenie RE, Avorn J, Tessema FA, Kesselheim AS. Public funding for transformative drugs: the case of sofosbuvir. Drug Discov Today 2021;26:273-281. [PMID: 33011345 PMCID: PMC7528745 DOI: 10.1016/j.drudis.2020.09.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 08/03/2020] [Accepted: 09/23/2020] [Indexed: 11/21/2022]
27
Conti RM, David FS. Public research funding and pharmaceutical prices: do Americans pay twice for drugs? F1000Res 2020;9:707. [PMID: 33204410 PMCID: PMC7642989 DOI: 10.12688/f1000research.24934.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/02/2020] [Indexed: 11/29/2022]  Open
28
Marshall LJ, Triunfol M, Seidle T. Patient-Derived Xenograft vs. Organoids: A Preliminary Analysis of Cancer Research Output, Funding and Human Health Impact in 2014-2019. Animals (Basel) 2020;10:ani10101923. [PMID: 33092060 PMCID: PMC7593921 DOI: 10.3390/ani10101923] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 10/13/2020] [Accepted: 10/15/2020] [Indexed: 12/14/2022]  Open
29
Sarpatwari A, Avorn J, Kesselheim AS. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation? BMJ 2020;371:m3841. [PMID: 33032982 DOI: 10.1136/bmj.m3841] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
30
Anwar A, Khan NA, Siddiqui R. Repurposing of Drugs Is a Viable Approach to Develop Therapeutic Strategies against Central Nervous System Related Pathogenic Amoebae. ACS Chem Neurosci 2020;11:2378-2384. [PMID: 32073257 DOI: 10.1021/acschemneuro.9b00613] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]  Open
31
Franzen N, Retèl VP, Schats W, van Harten WH. Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices. JAMA Oncol 2020;6:909-916. [DOI: 10.1001/jamaoncol.2019.6846] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
32
Hsiue EHC, Moore TJ, Alexander GC. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017. Clin Trials 2020;17:119-125. [PMID: 32114790 DOI: 10.1177/1740774520907609] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
33
Verbaanderd C, Rooman I, Meheus L, Huys I. On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients. Front Pharmacol 2020;10:1664. [PMID: 32076405 PMCID: PMC7006723 DOI: 10.3389/fphar.2019.01664] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Accepted: 12/19/2019] [Indexed: 12/12/2022]  Open
34
Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, Gyawali B, Addis A. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open 2019;9:e033728. [PMID: 31826897 PMCID: PMC6924817 DOI: 10.1136/bmjopen-2019-033728] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 11/10/2019] [Accepted: 11/11/2019] [Indexed: 11/04/2022]  Open
35
Long G. Federal government-interest patent disclosures for recent top-selling drugs. J Med Econ 2019;22:1261-1267. [PMID: 31190582 DOI: 10.1080/13696998.2019.1631832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
36
Choudhury MC, Saberwal G. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study. Orphanet J Rare Dis 2019;14:241. [PMID: 31684990 PMCID: PMC6829914 DOI: 10.1186/s13023-019-1224-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Accepted: 10/09/2019] [Indexed: 12/28/2022]  Open
37
Nayak RK, Avorn J, Kesselheim AS. Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ 2019;367:l5766. [PMID: 31645328 PMCID: PMC6812612 DOI: 10.1136/bmj.l5766] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/23/2019] [Indexed: 11/17/2022]
38
The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis 2019;14:225. [PMID: 31615551 PMCID: PMC6794821 DOI: 10.1186/s13023-019-1193-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 09/04/2019] [Indexed: 12/12/2022]  Open
39
Microgravity protein crystallization for drug development: a bold example of public sector entrepreneurship. JOURNAL OF TECHNOLOGY TRANSFER 2019. [DOI: 10.1007/s10961-019-09743-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
40
Karas L, Lu CY, Agrawal PB, Asgari MM. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers. J Am Acad Dermatol 2019;81:867-877. [PMID: 31103566 DOI: 10.1016/j.jaad.2019.05.025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 05/07/2019] [Accepted: 05/10/2019] [Indexed: 12/18/2022]
41
Gleeson D, Townsend B, Lopert R, Lexchin J, Moir H. Financial costs associated with monopolies on biologic medicines in Australia. AUST HEALTH REV 2019;43:36-42. [DOI: 10.1071/ah17031] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Accepted: 09/28/2017] [Indexed: 11/23/2022]
42
Fitipaldi H, McCarthy MI, Florez JC, Franks PW. A Global Overview of Precision Medicine in Type 2 Diabetes. Diabetes 2018;67:1911-1922. [PMID: 30237159 PMCID: PMC6152339 DOI: 10.2337/dbi17-0045] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Accepted: 07/07/2018] [Indexed: 01/01/2023]
43
Sinha MS, Kesselheim AS. The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2018;46:806-808. [PMID: 30336090 DOI: 10.1177/1073110518804246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
44
Fonseca R, Peneva D, Clancy Z, Abouzaid S, Jena AB. The Importance of Economic Trade-offs in Cancer Drug Pricing. Mayo Clin Proc 2018;93:976-979. [PMID: 29945732 DOI: 10.1016/j.mayocp.2018.05.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 04/30/2018] [Accepted: 05/15/2018] [Indexed: 10/28/2022]
45
Shameer K, Glicksberg BS, Hodos R, Johnson KW, Badgeley MA, Readhead B, Tomlinson MS, O’Connor T, Miotto R, Kidd BA, Chen R, Ma’ayan A, Dudley JT. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Brief Bioinform 2018;19:656-678. [PMID: 28200013 PMCID: PMC6192146 DOI: 10.1093/bib/bbw136] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Revised: 11/29/2016] [Indexed: 12/22/2022]  Open
46
Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. ANNALS OF TRANSLATIONAL MEDICINE 2018;6:166. [PMID: 29911114 DOI: 10.21037/atm.2018.03.28] [Citation(s) in RCA: 146] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
47
AlQuraishi M, Sorger PK. Reproducibility will only come with data liberation. Sci Transl Med 2018;8:339ed7. [PMID: 27194726 DOI: 10.1126/scitranslmed.aaf0968] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
48
Mimouni M, Krauthammer M, Abualhasan H, Badarni H, Imtanis K, Allon G, Berkovitz L, Blumenthal EZ, Mimouni FB, Amarilyo G. Publication outcome of abstracts submitted to the American Academy of Ophthalmology meeting. J Med Libr Assoc 2018;106:57-64. [PMID: 29339934 PMCID: PMC5764594 DOI: 10.5195/jmla.2018.314] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 09/01/2017] [Indexed: 11/24/2022]  Open
49
Murtazalieva KA, Druzhilovskiy DS, Goel RK, Sastry GN, Poroikov VV. How good are publicly available web services that predict bioactivity profiles for drug repurposing? SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2017;28:843-862. [PMID: 29183230 DOI: 10.1080/1062936x.2017.1399448] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 10/29/2017] [Indexed: 06/07/2023]
50
Hwang TJ, Kesselheim AS. Challenges in the Development of Novel Cardiovascular Therapies. Clin Pharmacol Ther 2017. [DOI: 10.1002/cpt.703] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA